Dexcom stock has gained 212.8% in a year’s time

DexCom, Inc. is an interesting health company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It successfully operates internationally with headquarters in San Diego, California, USA. Dexcom (DXCM) is the stock DXCM (NASDAQ). The large company's revenue was 1.032 billion USD in 2018. The big company had 3,900 employees in 2019.

You might think about which stock is better to buy: DexCom stock or Tandem Diabetes Care stock. Every diabetes partners company want to win in the long term. Dexcom's top competitors also include: VivaChek, HUMAN, Consensus Orthopedics and Eden Medical.

Dexcom's G6 CGM system has become popular to people with diabetes. DexCom's growth has been quite remarkable. The successful company's sales increased 44% year over year in the first quarter of 2020 to $405.1 million. DexCom is now highly profitable, much due to the success of the G6 system. Dexcom stock has gained 212.8% (compared with the industry’s growth of 14.3%) in a year’s time.

The Coronavirus Covid-19 Pandemic has created many uncertainties in the stock markets. However, the unfortunate viral outbreak hasn't seemed to negatively impact the company's finances. It's possible that the company could even experience a boost in sales as hospitals use the G6 CGM to monitor critically ill patients during the pandemic. Wall Street analysts certainly have projected that DexCom will generate average annual earnings growth of more than 50% over the next 5 years.

It's possible that Dexcom could achieve higher growth levels by expanding its market share outside the USA. Countries other than USA are not using CGM systems as heavily. DexCom is seeking growth and creating greater innovations. After the G6, comes the G7 CGM system (currently being worked on and on the way).

DexCom is an interesting healthcare stock to buy right now. DexCom is already profitable. DexCom can reinvest its earnings into expansion and research and development. The new G7 CGM system is on the way and the investors are looking forward to this exciting innovation. The DexCom valuation is high. The company can grow to the expectations of the hopeful investors. DexCom market share can increase.

DexCom (DXCM) is approaching its next earnings report date. On this date, DXCM is projected to report earnings of $0.28 per share, which would represent year-over-year growth of 250%.

Dexcom has useful products, such as: The Dexcom G6 CGM System, Dexcom G6 CGM Apps and Dexcom CLARITY.

The Dexcom G6 CGM System is here to help users. With the Dexcom G6 Continuous Glucose Monitoring (CGM) System, it is possible to know your glucose number and where it's headed at a glance. This helps to empower you to make more informed decisions about your diabetes management. Luckily, there are no fingersticks or calibrations required. Dexcom helps create the future of continuous glucose monitoring.

The Dexcom G6 CGM app is pretty useful. It is possible to have your continuous glucose monitoring system on your compatible smart device. Users can view their real-time glucose data, trends and alerts on their modern cell phones. It's possible to share data with friends, loved ones and caregivers. The App allows users to share their data with up to 5 Followers. Following requires installation of the Dexcom Follow app and a working Internet connection.

Dexcom CLARITY Diabetes Management Software is useful technology. Managing diabetes can be made easier with this fantastic software. Dexcom CLARITY creates simpler diabetes data reporting and management. Users of the software can get quick access to important insights that help in the assessment of health: highs, lows, daytime, nighttime and best day. Users can also find their estimated A1C, average glucose reading and risk for hypoglycemia. There are also more interesting statistics and features available.

The history of Dexcom is interesting. Dexcom was initially founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received USA Food and Drug Administration (FDA) approval. Dexcom launched the Dexcom STS Continuous Glucose Monitoring System. This system is a 3-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom later received approvals for other various innovative products. Dexcom has now enabled the sharing of data with up to 5 other people using the "Share" and "Follow" smartphone apps.

Here are the Dexcom Subsidiaries:

Nintamed GmbH & Co. KG

TypeZero Technologies LLC

Dexcom International Limited

DXCM Sweden AB

SweetSpot Diabetes Care, Inc.

DexCom Canada, Inc.

Alatheia Medical SA

NZ Medical and Scientific Ltd.

DexCom Austria GmbH

DexCom Philippines, Inc.

Dexcom (Uk) Limited

DexCom Canada, Co.